The disclosure generally relates to the compound of formula I, (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP-receptor antagonist. The disclosure also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cancer.本發明大體上係關於式I化合物(R)-N-(3-(7-甲基-1H-吲唑-5-基)-1-(4-(1-甲基哌啶-4-基)哌嗪-1-基)-1-側氧基丙-2-基)-4-(2-側氧基-1,2-二氫喹啉-3-基)哌啶-1-甲醯胺，包括醫藥學上可接受之鹽，其為CGRP受體拮抗劑。本發明亦係關於醫藥組合物及使用化合物治療CGRP相關病症之方法，該等病症包括偏頭痛、神經性血管擴張、神經性炎症、熱損傷、循環性休克、與停經相關之潮紅、諸如哮喘之氣管發炎疾病、慢性阻塞性肺病(COPD)及癌症。
